A
Anat Mirelman
Researcher at Tel Aviv Sourasky Medical Center
Publications - 246
Citations - 12440
Anat Mirelman is an academic researcher from Tel Aviv Sourasky Medical Center. The author has contributed to research in topics: Medicine & Gait (human). The author has an hindex of 47, co-authored 208 publications receiving 9246 citations. Previous affiliations of Anat Mirelman include Harvard University & Ben-Gurion University of the Negev.
Papers
More filters
Journal ArticleDOI
Gait Measures as Predictors of Poststroke Cognitive Function Evidence From the TABASCO Study
Einor Ben Assayag,Shani Shenhar-Tsarfaty,Amos D. Korczyn,Efrat Kliper,Hen Hallevi,Ludmila Shopin,Eitan Auriel,Nir Giladi,Anat Mike,Anat Halevy,Aner Weiss,Anat Mirelman,Natan M. Bornstein,Jeffrey M. Hausdorff +13 more
TL;DR: Results suggest that measures of balance and gait are significant risk markers of cognitive status 2 years after stroke, and relatively simple, performance-based tests of mobility may enhance the identification of stroke/transient ischemic attack survivors who have an increased risk of developing CD.
Journal ArticleDOI
Changes in event-related potentials during dual task walking in aging and Parkinson's disease.
Inbal Maidan,Firas Fahoum,Shiran Shustak,Eran Gazit,Dmitry Patashov,Dmitry Tchertov,Nir Giladi,Jeffrey M. Hausdorff,Anat Mirelman +8 more
TL;DR: Findings provide direct evidence of the physiological recruitment of attentional networks during walking and their impact by ageing and disease in older adults and patients with Parkinson's disease.
Journal ArticleDOI
A Multimodal Training Modulates Short Afferent Inhibition and Improves Complex Walking in a Cohort of Faller Older Adults With an Increased Prevalence of Parkinson's Disease.
Elisa Pelosin,Cecilia Cerulli,Carla Ogliastro,Giovanna Lagravinese,Laura Mori,Gaia Bonassi,Anat Mirelman,Jeffrey M. Hausdorff,Jeffrey M. Hausdorff,Jeffrey M. Hausdorff,Giovanni Abbruzzese,Roberta Marchese,Laura Avanzino +12 more
TL;DR: Treadmill training combined with non-immersive virtual reality induced an increase in inhibition of the SAI protocol on cortical excitability, improved obstacle negotiation performance and induced a reduction of the number of falls compared to treadmill training.
Journal ArticleDOI
Transcranial sonography and functional imaging in glucocerebrosidase mutation Parkinson disease
Mj J. Barrett,Johann Hagenah,Vijay Dhawan,Shichun Peng,Kaili Stanley,Deborah Raymond,Andres Deik,Sj J. Gross,Sj J. Gross,Nicole Schreiber-Agus,Anat Mirelman,Anat Mirelman,Karen Marder,Lj J. Ozelius,David Eidelberg,Sb B. Bressman,Sb B. Bressman,Rachel Saunders-Pullman,Rachel Saunders-Pullman +18 more
TL;DR: Both transcranial sonography and positron emission tomography are abnormal in GBA mutation associated Parkinson disease, similar to other Parkinson disease subjects.
Journal ArticleDOI
Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease
Dongbing Lai,Babak Alipanahi,Pierre Fontanillas,Tae-Hwi Schwantes-An,Jan O. Aasly,Roy N. Alcalay,Gary W. Beecham,Daniela Berg,Daniela Berg,Susan Bressman,Alexis Brice,Kathrin Brockman,Kathrin Brockman,Lorraine N. Clark,Mark R. Cookson,Sayantan Das,Vivianna M. Van Deerlin,Jordan Follett,Matthew J. Farrer,Joanne Trinh,Thomas Gasser,Thomas Gasser,Stefano Goldwurm,Emil K. Gustavsson,Christine Klein,Anthony E. Lang,J. William Langston,Jeanne C. Latourelle,Timothy Lynch,Karen Marder,Connie Marras,Eden R. Martin,Cory Y. McLean,Helen Mejia-Santana,Eric Molho,Richard H. Myers,Karen Nuytemans,Laurie J. Ozelius,Haydeh Payami,Deborah Raymond,Ekaterina Rogaeva,Michael P. Rogers,Owen A. Ross,Owen A. Ross,Ali Samii,Rachel Saunders-Pullman,Birgitt Schüle,Claudia Schulte,Claudia Schulte,William K. Scott,Caroline M. Tanner,Eduardo Tolosa,James E. Tomkins,Dolores Vilas,John Q. Trojanowski,Ryan J. Uitti,Jeffery M. Vance,Naomi P. Visanji,Zbigniew K. Wszolek,Cyrus P. Zabetian,Anat Mirelman,Nir Giladi,Avi Orr Urtreger,Paul Cannon,Brian K. Fiske,Tatiana Foroud +65 more
TL;DR: In this paper, the authors performed the first genome-wide association study of penetrance and age-at-onset of Parkinson's disease in LRRK2 mutation carriers (776 cases and 1,103 non-cases at their last evaluation).